The research team, led by neurosurgeons at one of China’s most prominent hospitals, enrolled 147 consecutive patients between May 2018 and August 2020, ultimately analyzing 140 individuals who completed preoperative assessments: 98 with glioma, the most common primary malignant brain tumor, and 42 with brain metastases, most frequently originating from lung cancer. Every patient filled out two of the most widely used patient-reported outcome instruments in oncology, the EORTC QLQ-C30 core questionnaire and the brain-cancer-specific QLQ-BN20 module, before surgery and again at seven days, one month, and three months afterward. The QLQ-C30 captures five functional domains—physical, role, emotional, cognitive, and social—alongside global health status and a battery of symptoms, while the QLQ-BN20 probes issues particularly relevant to brain tumor patients, including future uncertainty, motor dysfunction, communication deficit, headaches, seizures, and leg weakness.

The headline result is a striking V-shaped trajectory in overall health status. One week after surgery, patients reported significant deterioration across multiple domains: global health status, physical function, role function, fatigue, pain, and lower extremity weakness all worsened compared with preoperative baselines. Among glioma patients, physical function fell from a mean of 87.4 points to 66.4 on the 100-point scale, and role function dropped from 79.6 to 60.8, both highly statistically significant declines. Yet by the one-month follow-up, most functional measures in the glioma group had climbed back to baseline levels, and the recovery pattern held across low-grade glioma, high-grade glioma, and brain metastasis subgroups, with high-grade patients recovering more slowly.

Not every symptom followed the same curve. For glioma patients, seizure-related symptoms actually improved one month after surgery, a finding the authors attribute to the clinical effect of removing epileptic foci during tumor resection, potentially reinforced by standardized anti-epileptic medication. In the brain metastasis group, psychological distress eased over time: future uncertainty and headaches were significantly alleviated at the one-month mark, and cognitive function scores improved as well. On the other hand, some symptoms emerged or lingered later in recovery—dyspnea and bladder control worsened at one month in glioma patients, skin itching deteriorated at three months, and dyspnea was significantly exacerbated at three months in the metastasis group.

Beyond charting trajectories, the study used multivariate linear regression to identify which patient and treatment characteristics independently predicted quality-of-life outcomes at each time point. The list of influential factors was long and domain-specific. Age, years of education, tumor location and laterality, surgical extent, and baseline Karnofsky Performance Status all emerged as significant predictors of particular HRQoL domains. For example, seven days after surgery, older age, more education, and right-sided tumors were independently associated with less severe communication deficit among glioma patients. At one month, tumors spanning multiple lobes, subtotal resection, and gross total resection were linked to worse motor dysfunction scores, while occipital lobe tumors predicted better motor outcomes.

Some associations defied simple intuition. Among glioma patients, advanced age was linked to milder communication deficits and leg weakness after surgery—a counterintuitive result the researchers attribute largely to selection bias. Elderly patients with severe preoperative neurological deficits or multiple comorbidities are generally not candidates for craniotomy, so the older patients who made it into the study represented a relatively healthy group with better neurological reserve. In the brain metastasis cohort, by contrast, older patients tended to report higher levels of future uncertainty and headaches, possibly reflecting the psychological weight and complex disease course that accompany metastatic cancer.

Tumor laterality produced some of the study’s most mechanistically interesting findings. Left-hemisphere lesions were associated with more severe baseline communication impairment, consistent with the left hemisphere’s dominant role in language processing. Right-sided tumors, meanwhile, were linked to worse emotional, cognitive, and social function in the early postoperative period. The authors note that these patterns align with the well-documented functional lateralization of the human cerebrum and argue that recognizing hemispheric differences can help clinicians design individualized assessment plans and targeted rehabilitation for speech, cognition, and motor function.

The Karnofsky Performance Status score, a standard measure of a patient’s ability to perform daily activities, proved to be a crucial reference point throughout. KPS was negatively correlated with headache, fatigue, and pain, meaning patients with better functional status reported fewer of these core symptoms. Baseline quality of life also differed significantly across tumor grades: patients with low-grade glioma, high-grade glioma, and brain metastases showed distinct profiles in physical function, cognitive function, pain, insomnia, motor dysfunction, headache, and leg weakness. Brain metastasis patients generally carried a heavier symptom burden at baseline, likely because most had already undergone systemic treatment for their primary tumors before arriving at neurosurgery.

The authors are candid about the study’s limitations. Follow-up attrition was substantial—only 33.7 percent of glioma patients and 31 percent of brain metastasis patients completed the three-month assessment—and the researchers used multiple imputation to manage missing data, though sensitivity analyses were not feasible given the sample size. The single-center design, the relatively short three-month window, and the absence of detailed records on preoperative systemic therapies and postoperative adjuvant treatments all introduce potential bias. The team also performed a large number of statistical tests across domains, time points, and subgroups, which elevates the risk of false-positive findings, and they caution that the observed associations are population-specific and require external validation in larger, multi-center cohorts.

Even with those caveats, the study’s practical message is clear and actionable. Surgery on a malignant brain tumor reliably produces a transient dip in quality of life, but for most patients the functional nadir is temporary, with the majority of indicators recovering within a month. Because age, tumor laterality, surgical approach, and performance status each shape different aspects of recovery at different times, the authors argue that regular, structured assessment of these factors can help clinicians formulate individualized interventions—whether targeted supportive care in the first postoperative week, seizure management, cognitive rehabilitation, or psychological support for patients grappling with uncertainty about the future. In a disease where median survival for glioblastoma remains between 12 and 15 months, ensuring that the time patients have is lived as well as possible is not a secondary goal but a central measure of treatment success.

Subject of Research: Perioperative health-related quality of life and its determinants in patients with malignant brain tumors

Article Title: Health-related quality of life and its determinants in patients with malignant brain tumors: a prospective longitudinal study

Article References: Xiao, Z., Chen, W., Yang, T., Wang, Y., Li, J., Guo, X., Wang, L., Xu, D., Jiang, W., Zhang, Y., Wang, Y., & Ma, W. (2026). Health-related quality of life and its determinants in patients with malignant brain tumors: a prospective longitudinal study. Supportive Care in Cancer, 34(10), Article 1021. https://doi.org/10.1007/s00520-026-11262-0

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11262-0

Keywords: malignant brain tumors, glioma, brain metastases, health-related quality of life, EORTC QLQ-C30, EORTC QLQ-BN20, neurosurgery, Karnofsky Performance Status, patient-reported outcomes, perioperative care, longitudinal study, supportive care

PCNSL is a subtype of extranodal non-Hodgkin lymphoma that is confined to the brain, spinal cord, leptomeninges, or eyes, without systemic involvement at presentation. Its occurrence in the ventricles is notably rare, leading to limited collective clinical data and a paucity of systematic studies. Recognizing this knowledge gap, Prof. Li and his team embarked on a meticulous retrospective review involving 51 PCNSL cases with ventricular involvement, comprising 29 newly identified patients and 22 cases documented in prior literature. This expansive dataset offers an unprecedented opportunity to decode the clinical presentations, radiological fingerprints, pathological markers, and treatment responses associated with ventricular PCNSL.

Patients affected by ventricular PCNSL exhibited a median age of 53 years and a predominance of male patients. Symptomatically, the clinical picture diverged somewhat from typical PCNSL presentations elsewhere in the brain. The most prevalent complaint was persistent headache, which underscores the impact of mass effect and resultant intracranial pressure fluctuations within the ventricular system. Patients also reported dizziness, nausea, and deficits in vision and memory, along with limb weakness, emphasizing the multifocal neurologic dysfunction caused by tumor invasion or local edema. These symptoms are reflective of the ventricles’ deep midline location and their proximity to critical neuroanatomical structures that govern sensorimotor and cognitive functions.

Magnetic resonance imaging (MRI), a cornerstone in neuro-oncology diagnostics, revealed distinctive yet somewhat variable imaging traits of ventricular PCNSL. On T2-weighted sequences, the lesions predominantly appeared iso- to hypointense, with occasional hyperintensity in rare cases. Contrast-enhanced imaging consistently demonstrated robust enhancement coupled with peritumoral edema, hallmark signs of aggressive neoplastic behavior and disruption of the blood-brain barrier. Strikingly, features such as necrosis, cystic changes, or calcifications commonly seen in other brain tumors were absent, suggesting a relatively uniform tumor pathology. The median tumor size was substantial at 5.21 cm, and consequential obstructive hydrocephalus was identified in multiple patients, owing to tumor-induced blockage of CSF flow pathways.

From a molecular standpoint, immunohistochemical profiling provided critical insights into tumor biology. High positivity rates for BCL-2 and BCL-6 proteins – at 45.45% and 64.29% respectively – indicated active regulation of apoptosis and germinal center B-cell lineage traits, consistent with aggressive large B-cell lymphoma phenotypes. Furthermore, an elevated median Ki-67 proliferation index of 80% confirmed the marked mitotic activity and rapid cellular turnover characteristic of PCNSL, underscoring the tumor’s highly proliferative and invasive nature within the ventricular milieu.

When evaluating prognostic determinants, the study identified patient age exceeding 60 years and female gender as significant predictors of diminished survival outcomes. Remarkably, neither the choice of surgical intervention—ranging from gross tumor resection to stereotactic biopsy—nor the type of chemotherapy administered showed a statistically significant correlation with overall prognosis. This suggests that intrinsic host factors and tumor biology weigh more heavily on disease trajectory than treatment modality alone. Standard therapeutic approaches predominantly involved high-dose methotrexate-based chemotherapy, often preceded by surgical biopsy, reflecting current front-line armamentarium against PCNSL.

The study’s conclusions hold profound clinical implications. Despite the rare occurrence of PCNSL in the ventricles, the tumor’s biological behavior, radiologic characteristics, and pathological hallmarks largely parallel those observed in conventional PCNSL affecting cerebral parenchyma. Hence, treatment strategies applied universally for PCNSL remain applicable and effective for ventricular variants, reaffirming the role of methotrexate-centered chemotherapeutic protocols complemented by carefully considered surgical interventions tailored to individual patient factors.

This investigation not only enriches the scarce literature on ventricular PCNSL but also serves as a pivotal reference point for neuro-oncologists grappling with diagnostic and therapeutic dilemmas posed by these atypical tumor locations. The nuanced understanding of clinical manifestations and MRI features aids in earlier and more precise diagnosis, potentially mitigating the risk of delayed or misdirected treatment. Concurrently, molecular profiling fosters a glimpse into the pathogenetic mechanisms at play, opening avenues for targeted therapies and personalized medicine.

The research underscores the vital necessity for global collaborative efforts to aggregate and analyze rare tumor variants through multicenter studies and registries. Such endeavors can illuminate subtle variations in tumor biology and clinical response, catalyzing advancements in diagnostic accuracy and therapeutic efficacy. As emerging imaging technologies and molecular diagnostics evolve, integrating them into studies of ventricular PCNSL promises to refine prognosis and optimize patient management strategies.

In synthesizing a comprehensive clinical portrait of ventricular PCNSL, Prof. Li’s team provides clinicians with pragmatic evidence that bridges existing gaps, enabling data-driven decision-making for an otherwise elusive and formidable disease entity. Their work reinforces the principle that although anatomical rarity may challenge diagnostic vigilance, it does not necessarily mandate deviation from established oncologic principles. Ultimately, this study exemplifies rigorous scientific inquiry translating into enhanced patient care and underscores the resilience of multidisciplinary approaches in conquering complex neuro-oncological disorders.

As research continues to evolve, ongoing scrutiny of therapeutic outcomes and integration of novel treatment modalities such as immunotherapy and radiotherapy will be essential to improve survival and quality of life for patients facing ventricular PCNSL. Innovations in minimally invasive neurosurgical techniques also promise to ameliorate procedural risks and expand treatment options for these deep-seated tumors. Together, this collective progress offers renewed hope in confronting one of the most challenging facets of central nervous system malignancies.

Subject of Research: People

Article Title: Clinical characteristics and prognosis of ventricular primary central nervous system lymphoma: a case series and literature review

News Publication Date: 10-Oct-2025

Web References:

• DOI link: 10.1186/s41016-025-00410-w

Image Credits: Dr. Xuejun Li from Central South University, China

Keywords: Health and medicine, Clinical medicine, Diseases and disorders, Health care, Human health, Life sciences, Organismal biology, Tumor cells, Brain tumors, Cancer, Lymphoma, Medical treatments

Glioblastoma, characterized by its highly invasive nature and poor prognosis, remains one of the most formidable challenges in neuro-oncology. Despite advances in surgical resection and chemoradiotherapy, median survival barely surpasses 15 months. A critical obstacle has been the resilience of glioblastoma stem cells, a subpopulation endowed with self-renewal capacity and therapy resistance, which drive tumor recurrence and progression. The newly published study spearheaded by Díaz Méndez and colleagues elucidates a sophisticated regulatory axis involving androgen receptor signaling and microRNA-mediated gene silencing that directly modulates GSC sensitivity to TMZ.

Central to this discovery is the identification of a microRNA signature—comprising miR-1, miR-26a-1, and miR-487b—that orchestrates the silencing of two pivotal transcription factors, WT1 (Wilms Tumor 1) and FOXA1 (Forkhead Box A1). Both WT1 and FOXA1 have been previously implicated in tumor proliferation and stemness maintenance, yet their precise roles in glioblastoma chemoresistance had remained elusive. By inhibiting androgen receptor activity, the study reveals an upregulation of this triad of microRNAs, which in turn downregulates WT1 and FOXA1 expression, culminating in decreased viability and enhanced TMZ susceptibility of GSCs.

The androgen receptor, classically studied in prostate cancer, emerges here as a critical player in glioblastoma biology. Its inhibition was achieved using selective antagonists known to penetrate the blood-brain barrier, ensuring therapeutic relevance. Subsequent functional assays demonstrated that androgen receptor blockade not only impairs proliferation but also disrupts the stemness phenotype by modulating epigenetic and transcriptional programs via microRNA networks. This approach underscores the therapeutic potential of repurposing androgen receptor inhibitors, already clinically approved in other malignancies, for glioblastoma treatment.

Mechanistically, the study delves into the intricate gene regulatory networks, highlighting how the miR-1/miR-26a-1/miR-487b signature functions as a molecular switch. Elevated expression of these microRNAs induces silencing of WT1 and FOXA1 through post-transcriptional repression, thereby dismantling the transcriptional programs that sustain GSC survival and resistance. This multi-layered suppression underscores the power of microRNA-mediated regulatory cascades in fine-tuning oncogenic pathways and modulating therapeutic responses.

Clinically, these findings are particularly significant as temozolomide resistance remains a substantial barrier in glioblastoma management. The standard treatment paradigm combines surgical resection with concurrent chemoradiotherapy, yet resistance mechanisms often thwart lasting remission. Enhancing TMZ efficacy through androgen receptor inhibition could substantially improve patient outcomes by sensitizing the refractory GSC compartment, which is integral to tumor regeneration.

The translational implications extend beyond the laboratory, suggesting that biomarker-driven patient stratification might identify individuals who would most benefit from combined androgen receptor antagonist and TMZ regimens. Assessing the expression profiles of androgen receptor, the implicated microRNAs, and downstream targets WT1 and FOXA1 in patient-derived samples could guide precision medicine approaches tailored to tumor molecular portraits.

Moreover, this research provides a conceptual framework to explore androgen receptor signaling in other brain tumors and possibly in treatment resistance across various cancer stem cell types. The cross-talk between nuclear hormone receptors and microRNA landscapes emerges as a fertile ground for novel therapeutic strategies, with the capacity to disrupt cancer stemness and chemoresistance pathways more broadly.

Future investigations are warranted to delineate the precise molecular interactions governing androgen receptor regulation of microRNA biogenesis in glioblastoma, as well as to optimize dosing and delivery methods of androgen receptor inhibitors for maximal intracranial efficacy. Additionally, integrating this approach with other emerging modalities such as immunotherapy could synergistically enhance anti-glioblastoma effects.

In summary, the meticulous work by Díaz Méndez et al. not only illuminates the underappreciated role of androgen receptor signaling in glioblastoma stem cell biology but also demonstrates a compelling strategy to enhance temozolomide sensitivity through a defined miRNA-mediated silencing mechanism targeting WT1 and FOXA1. This paradigm-shifting insight stands to invigorate the development of more effective, targeted glioblastoma therapies and provides hope for improved patient prognosis in a disease that has long resisted cure.

This study exemplifies the power of integrating molecular oncology with targeted therapeutics, revealing how modulation of regulatory RNAs can reprogram cancer stem cell dynamics and overcome formidable barriers to treatment. As the scientific community continues to unravel the complex biology of glioblastoma, such innovative approaches will be instrumental in transforming clinical practice and extending survival for patients afflicted by this devastating disease.

Subject of Research:
Androgen receptor inhibition and its effect on temozolomide sensitivity in glioblastoma stem cells mediated through a specific microRNA signature targeting WT1 and FOXA1.

Article Title:
Androgen receptor inhibition sensitizes glioblastoma stem cells to temozolomide by the miR-1/miR-26a-1/miR-487b signature mediated WT1 and FOXA1 silencing.

Article References:
Díaz Méndez, A.B., Di Giuliani, M., Sacconi, A. et al. Cell Death Discov. 11, 248 (2025). https://doi.org/10.1038/s41420-025-02517-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02517-6